Journal Mobile Options
Table of Contents
Vol. 37, Suppl. 3, 2000
Issue release date: May 2000
Section title: Paper
Eur Urol 2000;37(suppl 3):1–9
(DOI:10.1159/000052386)

Treatment of Superficial Bladder Tumors: Achievements and Needs

Kurth K.H.a · Bouffioux C.b · Sylvester R.c · van der Meijden A.P.M.d · Oosterlinck W.e · Brausi M.f
aDepartment of Urology, Academic Medical Center, University of Amsterdam, The Netherlands; bDepartment of Urology, CHU Sart-Tilman/Domaine Universitaire du Sart Tilman, Liège, cEORTC Data Center, Brussels, Belgium; dDepartment of Urology, Bosch Medicentrum-Groot Ziekengasthuis, ’s-Hertogenbosch, The Netherlands; eDepartment of Urology, Universitair Ziekenhuis Gent, Belgium; fDepartment of Urology, Istituto Scientifico H.S. Raffaele, Milano, Italy

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact service@karger.com


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 5/5/2000
Issue release date: May 2000

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISSN: 0302-2838 (Print)
eISSN: 1421-993X (Online)

For additional information: http://www.karger.com/EUR

Abstract

Objective: The therapeutic objectives in the initial treatment of superficial tumors are to remove completely the tumor, to assess the need for further therapy and to plan the follow-up. Methods/Results: The EORTC Genitourinary Group assessed the percentage of patients with recurrence at 3 months (3RR) after complete resection of all visible lesions taking into account the institution, the number of tumors at presentation and the year of treatment. The 3RR was considered for 18 institutions. For single tumors, the 3RR varied from 0 to 36% and for multiple tumors from 7 to 75%. The 3RR by number of tumors was 8.7% for single tumors, 21% for 2–5 tumors and 32.2% for >5 tumors. The 3RR by year of entry for single tumors ranged from 21.0 to 43.8% during 1975–1978, from 6.3 to 12.7% during 1984–1986 and from 3 to 5.3% during 1987–1989. For multiple tumors it ranged from 50.0 to 61.5% during 1975–1978, from 20.2 to 27.3% during 1979–1983 and from 14.4 to 24.6% during 1984– 1986. The use of more refined instruments probably led to the decreasing percentage of the 3RR in more recent years, the large variation between institutions remains unexplained. The bladder’s unique location renders its mucosa accessible to instillation of chemotherapeutic and immunotherapeutic agents. Cytostatics can be instilled into the bladder hours after surgery without severe complications. A single early instillation within 6 h after transurethral resection (TUR) in patients with a solitary bladder tumor category Ta/T1G1 to G3 could reduce the recurrence rate per year by nearly 50%. The superiority of any of the commonly used intravesical drugs has never been demonstrated; the time to initiate therapy is important for treatment outcome. Optimal results can be achieved by initiating treatment early (within 24 h after TUR) and for a duration of 6 months, and maintenance (>6 months) for patients with a delayed first instillation (>7 days after TUR). Bacillus Calmette-Guérin (BCG) immunotherapy has been confirmed to be highly effective in the reduction of tumor recurrence, the treatment of residual papillary transitional cell carcinoma and the treatment of carcinoma in situ (CIS). The response rate in the treatment of the papillary disease averages 55%, and for CIS 73%. In the prevention of tumor recurrence the relative benefit of BCG is 45%. A direct prospective randomized comparison of BCG with intravesical chemotherapy has found it to be significantly superior to thiotepa, to doxorubicin and to mitomycin C when only patients with intermediate and high risk for recurrence were treated. In studies including patients with low recurrence risk, no advantage for BCG was found. Clinical trials showed no superiority of BCG immunotherapy to chemotherapy in preventing progression to ≧T2. Conclusions: Investigation of the concept of chemoimmunotherapy up to now lacked evidence of advantages for this approach. Preventive regulatory measures directed to decrease tobacco smoking and some occupational exposures to aromatic amines may contribute to the reduction of bladder cancer. Bladder cancer is a multistep process making this tumor a candidate for chemoprevention. To date, retinoids are the best-studied chemopreventive agents achieving mixed clinical results in superficial bladder tumors. The potent apoptosis-inducing retinoid fenretinide is currently in the phase III trials. The follow-up of patients with all types of superficial tumors must be lifelong; unfortunately cystoscopy cannot be replaced yet by the control of any markers present or not in the urine. There is hope this may change in the near future.

© 2000 S. Karger AG, Basel


  

Author Contacts

Prof. K.H. Kurth
Department of Urology/G4-216, Academic Medical Center
University of Amsterdam, Meibergdreef 9
NL–1105 AZ Amsterdam (The Netherlands)
Tel. +31 20 5663775/5666030, Fax +31 20 6911389, E-Mail K.H.Kurth@amc.uva.nl

  

Article Information

Number of Print Pages : 9
Number of Figures : 0, Number of Tables : 0, Number of References : 67

  

Publication Details

European Urology
Official Organ of the European Association of Urology

Vol. 37, No. Suppl. 3, Year 2000 (Cover Date: Released May 2000)

Journal Editor: C.C. Schulman, Brussels
ISSN: 0302–2838 (print), 1421–993X (Online)

For additional information: http://www.karger.ch/journals/eur


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 5/5/2000
Issue release date: May 2000

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISSN: 0302-2838 (Print)
eISSN: 1421-993X (Online)

For additional information: http://www.karger.com/EUR


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.